ClinicalTrials.gg
CompletedNCT02961881Updated Feb 2, 2024Results posted

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

A Phase 1 interventional study of blinatumomab in Non-Hodgkin's Lymphoma, sponsored by Amgen. Completed at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Lymphoma, Non-Hodgkin by Amgen — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Amgen.

Enrollment
9th of 15
35 · median 39
Started
2017
the only one that year
Phase 1
7 of 20
none open now
Registered
19th of 20
by date

Among the 20 studies in Lymphoma, Non-Hodgkin by Amgen, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2017, is one of 7 in phase 1, and was the 19th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 20 studies in Lymphoma, Non-Hodgkin by Amgen is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Lymphoma, Non-Hodgkin by Amgen as a file.
02

Study summary

Primary Objective:

  • To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations

Secondary Objectives:

  • To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations
  • To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously
  • To determine the incidence of anti-blinatumomab antibody formation following SC administration
  • To evaluate efficacy response following treatment with SC blinatumomab administration

Exploratory Objective:

  • To determine the pharmacodynamics (PD) time profiles for B-and T-lymphocytes as well as cytokine profiles during SC administration
  • To evaluate efficacy response following treatment with SC blinatumomab administration using Lugano criteria if positron emission tomography-computed tomography (PET/CT) is used for evaluation
03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject or subject's legally acceptable representative has provided .
  • Age greater than or equal to 18 years old at the time of informed consent
  • Subjects must have a histologically determined B cell NHL subtype as defined in the bullets below.

In addition, they must have disease that is primary after initial therapy or have relapsed disease.

  • Follicular Lymphoma I, II, IIIA
  • Marginal zone lymphoma (extranodal, nodal or splenic). Subjects with gastric mucosa-
  • associated lymphoid tissue must have progressed after Helicobacter pylori therapy and
  • radiation. Subjects with splenic marginal zone lymphoma must have prior splenectomy.
  • Lymphoplasmocytic lymphoma
  • Mantle cell lymphoma ([MCL] with the exception of aggressive MCL, defined as Ki67 > 30%,
  • or blastoid histology)
  • Small lymphocytic lymphoma

    • Subjects without standard therapy alternatives, or for standard therapy by investigator, or subjects unwilling to receive standard therapy. Disease status must be 1 of the following:
  • Primary refractory (at least 1 )
  • Relapsed within 1 year of first response
  • Responded to initial therapy for ≥ 1 year and relapsed after 2 or more lines of therapy, including an anti-CD20 monoclonal antibody

    • that has not been previously irradiated on positron emission tomography- computed tomography (PET-CT), or computed tomography (CT), of at least 1.5 cm within the last 21 days before the start of IP treatment.
    • (ECOG) performance status less than or equal to 2
    • greater than or equal to 3 months as determined by treating physician.
    • Subjects must have adequate organ and marrow at screening as defined below:
  • peripheral neutrophils >500/µL prior to start of treatment
  • ≥8 g/dL
  • greater than or equal to 50,000 mcL
  • (AST)/Alanine aminotransferase (ALT) \< 5 × (ULN
  • Total less than or equal to 1.5 x upper limit of normal (ULN)
  • greater than or equal to 50 mL/min (Cockcroft-Gault)

Exclusion criteria

Exclusion Criteria:

  • Currently receiving treatment in another device or drug study, or less than 30 days between ending treatment on another investigational device or drug study(ies) and start of IP treatment. Other investigational procedures while participating in this study are excluded.
  • Known to immunoglobulins or any other component of the study drug
  • Subject likely to not be available to complete all protocol required study visits or procedures to the best of the subject and investigator's knowledge
  • History or evidence of any other disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation procedures or completion.
  • Subjects who have had treatments with anti-cancer agents including rituximab or obinutuzumab and/or other monoclonal antibody or radioimmunotherapy within 6 weeks before the starting IP treatment.
  • stem cell transplantation within 12 weeks before the starting IP treatment or past history of allogeneic stem cell transplantation.
  • Subjects who have received anti-CD 19 targeted therapies, chimeric antigen receptor T-cell or other cellular therapies for the treatment of their lymphoma .
  • Subjects with suspected or known should be excluded from this clinical study because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Infection with (HIV) or chronic infection with virus or virus.
  • History of or current relevant central nervous system pathology such as epilepsy, recurrent seizures, paresis, aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome or psychosis.
  • History of other than their lymphoma with the exception of:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment and felt to be at low risk for recurrence by the treating physician.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
    • Adequately treated breast ductal carcinoma in situ without evidence of disease
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
    • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or uncontrolled systemic fungal bacteria, viral, or other infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • A female who is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 48 hours (Period 1) or 96 hours (Period 2), respectively, after the last dose of blinatumomab (Female subjects of should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test).
  • A female of childbearing potential unwilling to use highly effective method of during treatment and for an additional 48 hours (Period 1) or 96 hours (Period 2), respectively, after the last dose of blinatumomab.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    blinatumomab

    Drug: blinatumomab

Interventions

  • Blinatumomab used as both continuous IV infusion and subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration

    The occurrence of any of the following toxicities during the DLT evaluation period was considered a DLT, if judged by the investigator to be related to the administration of blinatumomab: * Death * Any toxicity, regardless of grade, that lead to a participant's removal from the study by the investigator and/or sponsor * Persistent Common Terminology Criteria for Adverse Events (CTCAE) grade \>/= 2 non-hematologic adverse events (AEs) that were deemed intolerable by the participant or the treating physician and that did not respond to appropriate medical management within 5 days and lead to treatment discontinuation * Recurrent grade 2 seizures * All grade 3 and 4 AEs and laboratory abnormalities, which occurred during the SC administration portion of the treatment period with exceptions noted in protocol section 6.2.1.2.3.

    Time frame: Day 1 to Day 7 of Week 4

  2. Number of Participants With DLTs CTCAE Grade ≥ 3 After SC Administration

    All toxicities were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

    Time frame: Day 1 to Day 7 of Week 4

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs) After SC Administration

    An AE was defined as any untoward medical occurrence in a clinical study participant. The AE did not necessarily have a causal relationship with study treatment. The definition of AEs included worsening of a pre-existing medical condition. TEAEs included AEs starting on or after first dose of investigational product and up to the end of study date. All AEs were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

    Time frame: Day 1 to end of study (approximately 17 weeks)

Secondary outcomes

  1. Steady State Serum Concentration (Css) of Blinatumomab After cIV Administration

    Summarized as the observed concentrations collected after 5 half-lives after the start of the IV infusion of each dose (i.e., 9, 28 and 112 μg/day).

    Time frame: Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6

  2. Systemic Clearance (CL) of Blinatumomab After cIV Administration

    Calculated as CL=R0/Css; where R0 is the infusion rate (μg/hr) and Css is the average Css. Both R0 and Css were dose-normalized to 112 μg/day for this calculation.

    Time frame: Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6

  3. Maximum Observed Concentration (Cmax) of Blinatumomab After SC Administration

    Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  4. Time at Which Cmax (Tmax) Occurred of Blinatumomab After SC Administration

    Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  5. Area Under the Concentration-time Curve (AUC) of Blinatumomab After SC Administration for a Dosing Interval t (AUCt)

    Estimated using the linear trapezoidal method; where t is a dosing interval. AUC over the dosing interval, t where t is 12 hours for Cohorts 1 and 2, 24 hours for Cohorts 3 and 4, and 48 hours for Cohort 5.

    Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  6. Minimum Observed Concentration (Cmin) of Blinatumomab After SC Administration

    Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  7. Apparent Clearance (CL/F) of Blinatumomab After SC Administration

    Calculated as CL/F = Dose sc / AUCt-ss (at steady state).

    Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  8. Volume of Distribution Based on Terminal Phase (Vz/F) of Blinatumomab After SC Administration

    Calculated as Vz/F=CL/F / λz, where λz was the first-order rate constant estimated via linear regression of the terminal log-linear decay phase as determined from the noncompartmental analysis.

    Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  9. Terminal Half-life (t1/2,z) of Blinatumomab After SC Administration

    Calculated as t1/2,z = ln(2) / λz.

    Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  10. Accumulation Ratio of Blinatumomab After SC Administration

    Calculated as the ratio of AUCt (last SC dose; Week 4 Day 5) / AUC (first SC dose; Week 4 Day 1).

    Time frame: Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  11. Bioavailability (F) of SC Blinatumomab

    Calculated as F = (CL \* AUCt-ss) / Dose sc.

    Time frame: Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)

  12. Maximum Tolerated Dose (MTD) of SC Blinatumomab

    The MTD was defined as the highest dose level at which \</= 1 of 6 participants experienced a DLT.

    Time frame: Day 1 to Day 7 of Week 4

  13. Number of Participants With Anti-blinatumomab Antibody Formation After SC Administration

    Time frame: Predose at the re-start of cIV infusion (Week 5 Day 1)

  14. Overall Response Rate (ORR) After SC Administration

    Percentage of participants achieving ORR (complete response \[CR\] + partial response \[PR\]) was determined by best overall response using Cheson criteria: * CR: disappearance of all evidence of disease. * PR: regression of measurable disease and no new sites. The 95% confidence interval (CI) was calculated using Clopper-Pearson exact CI. Participants were considered as non-responders if there was no response assessment available.

    Time frame: Day 1 to end of study (approximately 17 weeks)

07

Results

Posted Feb 2, 2024

Participant flow

Of the 39 participants screened, 35 participants were enrolled at 10 centers in the United States, Europe and Australia between 18 September 2017 and 02 September 2021.

Participant flow — Overall Study
MilestoneBlinatumomab Cohort 1Blinatumomab Cohort 2Blinatumomab Cohort 3Blinatumomab Cohort 4Blinatumomab Cohort 5
Started78866
Started week 4 sc dosing67765
Started week 5-6 civ dosing65665
Completed54565
Not completed24301
Withdrew: Adverse event12201
Withdrew: Participant request02000
Withdrew: Disease progression10100

Outcome measures

PrimaryNumber of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration

The occurrence of any of the following toxicities during the DLT evaluation period was considered a DLT, if judged by the investigator to be related to the administration of blinatumomab: * Death * Any toxicity, regardless of grade, that lead to a participant's removal from the study by the investigator and/or sponsor * Persistent Common Terminology Criteria for Adverse Events (CTCAE) grade \>/= 2 non-hematologic adverse events (AEs) that were deemed intolerable by the participant or the treating physician and that did not respond to appropriate medical management within 5 days and lead to treatment discontinuation * Recurrent grade 2 seizures * All grade 3 and 4 AEs and laboratory abnormalities, which occurred during the SC administration portion of the treatment period with exceptions noted in protocol section 6.2.1.2.3.

Time frame:
Day 1 to Day 7 of Week 4
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration
ParticipantsBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration01100
PrimaryNumber of Participants With DLTs CTCAE Grade ≥ 3 After SC Administration

All toxicities were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

Time frame:
Day 1 to Day 7 of Week 4
Reported as:
Count of participants · Participants
Number of Participants With DLTs CTCAE Grade ≥ 3 After SC Administration
ParticipantsBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Number of Participants With DLTs CTCAE Grade ≥ 3 After SC Administration01100
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) After SC Administration

An AE was defined as any untoward medical occurrence in a clinical study participant. The AE did not necessarily have a causal relationship with study treatment. The definition of AEs included worsening of a pre-existing medical condition. TEAEs included AEs starting on or after first dose of investigational product and up to the end of study date. All AEs were graded using the CTCAE version 4.0: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

Time frame:
Day 1 to end of study (approximately 17 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) After SC Administration
ParticipantsBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Any TEAEs26664
Any TEAEs CTCAE Grade ≥ 311210
SecondarySteady State Serum Concentration (Css) of Blinatumomab After cIV Administration

Summarized as the observed concentrations collected after 5 half-lives after the start of the IV infusion of each dose (i.e., 9, 28 and 112 μg/day).

Time frame:
Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6
Reported as:
Geometric mean · pg/mL
Steady State Serum Concentration (Css) of Blinatumomab After cIV Administration
pg/mLBlinatumomab cIV Before SC Week 1Blinatumomab cIV Before SC Week 2Blinatumomab cIV Before SC Week 3Blinatumomab cIV After SC
Steady State Serum Concentration (Css) of Blinatumomab After cIV Administration238 ± 137672 ± 942780 ± 872700 ± 85
SecondarySystemic Clearance (CL) of Blinatumomab After cIV Administration

Calculated as CL=R0/Css; where R0 is the infusion rate (μg/hr) and Css is the average Css. Both R0 and Css were dose-normalized to 112 μg/day for this calculation.

Time frame:
Once at any timepoint during Day 2 of Weeks 1, 2, 3, 5 and 6
Reported as:
Geometric mean · L/hr
Systemic Clearance (CL) of Blinatumomab After cIV Administration
L/hrBlinatumomab cIV Before SCBlinatumomab cIV After SC
Systemic Clearance (CL) of Blinatumomab After cIV Administration1.67 ± 1111.73 ± 85
SecondaryMaximum Observed Concentration (Cmax) of Blinatumomab After SC Administration
Time frame:
Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · pg/mL
Maximum Observed Concentration (Cmax) of Blinatumomab After SC Administration
pg/mLBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohorts 4 and 5Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Week 4 Day 1877 ± 881810 ± 932650 ± 984260 ± 103——
Week 4 Day 52070 ± 154340 ± 364290 ± 98—5690 ± 714340 ± 304
SecondaryTime at Which Cmax (Tmax) Occurred of Blinatumomab After SC Administration
Time frame:
Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Median · hours
Time at Which Cmax (Tmax) Occurred of Blinatumomab After SC Administration
hoursBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohorts 4 and 5Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Week 4 Day 15.0 (0.0 to 8.1)7.9 (1.0 to 8.1)12 (7.2 to 12)12 (1.9 to 12)——
Week 4 Day 52.8 (0.0 to 8.0)4.0 (0.0 to 6.1)7.6 (6.0 to 12)—8.0 (4.0 to 12)9.5 (2.2 to 12)
SecondaryArea Under the Concentration-time Curve (AUC) of Blinatumomab After SC Administration for a Dosing Interval t (AUCt)

Estimated using the linear trapezoidal method; where t is a dosing interval. AUC over the dosing interval, t where t is 12 hours for Cohorts 1 and 2, 24 hours for Cohorts 3 and 4, and 48 hours for Cohort 5.

Time frame:
Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · hr•pg/mL
Area Under the Concentration-time Curve (AUC) of Blinatumomab After SC Administration for a Dosing Interval t (AUCt)
hr•pg/mLBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Week 4 Day 16080 ± 809430 ± 40———
Week 4 Day 519100 ± 2140500 ± 4172000 ± 9290900 ± 7790800 ± 236
SecondaryMinimum Observed Concentration (Cmin) of Blinatumomab After SC Administration
Time frame:
Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · pg/mL
Minimum Observed Concentration (Cmin) of Blinatumomab After SC Administration
pg/mLBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Week 4 Day 1651 ± 931470 ± 101———
Week 4 Day 51290 ± 302550 ± 411950 ± 942130 ± 104147 ± 66
SecondaryApparent Clearance (CL/F) of Blinatumomab After SC Administration

Calculated as CL/F = Dose sc / AUCt-ss (at steady state).

Time frame:
Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) of Blinatumomab After SC Administration
L/hrBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Apparent Clearance (CL/F) of Blinatumomab After SC Administration5.85 ± 215.55 ± 416.25 ± 927.43 ± 777.43 ± 236
SecondaryVolume of Distribution Based on Terminal Phase (Vz/F) of Blinatumomab After SC Administration

Calculated as Vz/F=CL/F / λz, where λz was the first-order rate constant estimated via linear regression of the terminal log-linear decay phase as determined from the noncompartmental analysis.

Time frame:
Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · liters
Volume of Distribution Based on Terminal Phase (Vz/F) of Blinatumomab After SC Administration
litersBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Volume of Distribution Based on Terminal Phase (Vz/F) of Blinatumomab After SC Administration83.4 ± 19100 ± 9358.6 ± 115120 ± 97133 ± 9623
SecondaryTerminal Half-life (t1/2,z) of Blinatumomab After SC Administration

Calculated as t1/2,z = ln(2) / λz.

Time frame:
Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · hours
Terminal Half-life (t1/2,z) of Blinatumomab After SC Administration
hoursBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Terminal Half-life (t1/2,z) of Blinatumomab After SC Administration9.87 ± 1210.7 ± 227.30 ± 2111.7 ± 309.20 ± 83
SecondaryAccumulation Ratio of Blinatumomab After SC Administration

Calculated as the ratio of AUCt (last SC dose; Week 4 Day 5) / AUC (first SC dose; Week 4 Day 1).

Time frame:
Week 4 Day 1 (pre-dose and 1, 2, 4, 6, 8 and 12 hours post-dose) and Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · ratio
Accumulation Ratio of Blinatumomab After SC Administration
ratioBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Accumulation Ratio of Blinatumomab After SC Administration3.25 ± 614.14 ± 352.31 ± 631.71 ± 1091.01 ± 107
SecondaryBioavailability (F) of SC Blinatumomab

Calculated as F = (CL \* AUCt-ss) / Dose sc.

Time frame:
Week 4 Day 5 (pre-dose and 1, 2, 4, 6, 8, 12, 24 and 48 hours post-dose)
Reported as:
Geometric mean · percent bioavailability
Bioavailability (F) of SC Blinatumomab
percent bioavailabilityBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Bioavailability (F) of SC Blinatumomab32.1 ± 3822.5 ± 5433.8 ± 21524.6 ± 5330.2 ± 180
SecondaryMaximum Tolerated Dose (MTD) of SC Blinatumomab

The MTD was defined as the highest dose level at which \</= 1 of 6 participants experienced a DLT.

Time frame:
Day 1 to Day 7 of Week 4
Reported as:
Number · μq
Maximum Tolerated Dose (MTD) of SC Blinatumomab
μqBlinatumomab SC Total
Maximum Tolerated Dose (MTD) of SC BlinatumomabNA
SecondaryNumber of Participants With Anti-blinatumomab Antibody Formation After SC Administration
Time frame:
Predose at the re-start of cIV infusion (Week 5 Day 1)
Reported as:
Count of participants · Participants
Number of Participants With Anti-blinatumomab Antibody Formation After SC Administration
ParticipantsBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Number of Participants With Anti-blinatumomab Antibody Formation After SC Administration00000
SecondaryOverall Response Rate (ORR) After SC Administration

Percentage of participants achieving ORR (complete response \[CR\] + partial response \[PR\]) was determined by best overall response using Cheson criteria: * CR: disappearance of all evidence of disease. * PR: regression of measurable disease and no new sites. The 95% confidence interval (CI) was calculated using Clopper-Pearson exact CI. Participants were considered as non-responders if there was no response assessment available.

Time frame:
Day 1 to end of study (approximately 17 weeks)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) After SC Administration
percentage of participantsBlinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5
Overall Response Rate (ORR) After SC Administration66.7 (22.3 to 95.7)71.4 (29.0 to 96.3)71.4 (29.0 to 96.3)83.3 (35.9 to 99.6)40.0 (5.3 to 85.3)

Adverse events

Collected over Day 1 to end of study (approximately 17 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab cIV Before SC Week 11/35 (2.9%)5/35 (14.3%)23/35 (65.7%)
Blinatumomab cIV Before SC Week 20/34 (0%)5/34 (14.7%)22/34 (64.7%)
Blinatumomab cIV Before SC Week 30/33 (0%)8/33 (24.2%)23/33 (69.7%)
Blinatumomab SC Cohort 10/6 (0%)0/6 (0%)2/6 (33.3%)
Blinatumomab SC Cohort 20/7 (0%)1/7 (14.3%)6/7 (85.7%)
Blinatumomab SC Cohort 30/7 (0%)1/7 (14.3%)6/7 (85.7%)
Blinatumomab SC Cohort 40/6 (0%)0/6 (0%)6/6 (100%)
Blinatumomab SC Cohort 50/5 (0%)0/5 (0%)4/5 (80%)
Blinatumomab cIV After SC1/28 (3.6%)10/28 (35.7%)19/28 (67.9%)
Blinatumomab SC Total0/31 (0%)2/31 (6.5%)24/31 (77.4%)
Blinatumomab cIV Total2/35 (5.7%)18/35 (51.4%)34/35 (97.1%)
Blinatumomab SC + cIV Total2/35 (5.7%)19/35 (54.3%)35/35 (100%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventBlinatumomab cIV Before SC Week 1Blinatumomab cIV Before SC Week 2Blinatumomab cIV Before SC Week 3Blinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5Blinatumomab cIV After SCBlinatumomab SC TotalBlinatumomab cIV TotalBlinatumomab SC + cIV Total
Erosive oesophagitisGastrointestinal disorders0/350/340/330/61/70/70/60/50/281/310/351/35
AphasiaNervous system disorders0/350/340/330/61/70/70/60/51/281/311/352/35
SeizureNervous system disorders0/350/340/330/60/71/70/60/50/281/310/351/35
HallucinationPsychiatric disorders0/350/340/330/60/71/70/60/50/281/310/351/35
Nervous system disorderNervous system disorders0/351/342/330/60/70/70/60/51/280/314/354/35
Cytokine release syndromeImmune system disorders0/350/342/330/60/70/70/60/52/280/312/352/35
Cognitive disorderNervous system disorders0/350/340/330/60/70/70/60/52/280/312/352/35
PyrexiaGeneral disorders0/351/340/330/60/70/70/60/51/280/312/352/35
PneumoniaInfections and infestations1/351/340/330/60/70/70/60/50/280/312/352/35
SepsisInfections and infestations0/350/341/330/60/70/70/60/51/280/312/352/35
Most frequent other events
Showing 10 of 81
Most frequent other events
EventBlinatumomab cIV Before SC Week 1Blinatumomab cIV Before SC Week 2Blinatumomab cIV Before SC Week 3Blinatumomab SC Cohort 1Blinatumomab SC Cohort 2Blinatumomab SC Cohort 3Blinatumomab SC Cohort 4Blinatumomab SC Cohort 5Blinatumomab cIV After SCBlinatumomab SC TotalBlinatumomab cIV TotalBlinatumomab SC + cIV Total
PyrexiaGeneral disorders7/353/3411/331/60/71/70/60/54/282/3117/3518/35
HeadacheNervous system disorders4/353/346/330/62/71/70/60/57/283/3115/3516/35
ConstipationGastrointestinal disorders6/353/344/330/61/70/70/60/53/281/3113/3514/35
Cytokine release syndromeImmune system disorders2/351/341/330/61/70/71/62/50/284/314/356/35
TremorNervous system disorders4/351/349/330/60/70/72/60/54/282/3112/3512/35
NeurotoxicityNervous system disorders3/351/343/331/61/70/72/60/52/284/315/357/35
VertigoEar and labyrinth disorders1/350/342/330/62/70/70/60/51/282/313/353/35
HypokalaemiaMetabolism and nutrition disorders0/351/340/330/62/70/70/60/50/282/311/353/35
AphasiaNervous system disorders0/350/341/330/60/72/70/60/51/282/312/353/35
InsomniaPsychiatric disorders3/352/340/330/61/71/71/60/52/283/317/359/35

Baseline characteristics

All enrolled participants.

Age, Customized
Age, Customized(Participants)Blinatumomab Cohort 1Blinatumomab Cohort 2Blinatumomab Cohort 3Blinatumomab Cohort 4Blinatumomab Cohort 5Total
18 - 64 years5533521
65 - 74 years2253113
75 - 84 years010001
≥ 85 years000000
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab Cohort 1Blinatumomab Cohort 2Blinatumomab Cohort 3Blinatumomab Cohort 4Blinatumomab Cohort 5Total
Female3453116
Male4433519
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Blinatumomab Cohort 1Blinatumomab Cohort 2Blinatumomab Cohort 3Blinatumomab Cohort 4Blinatumomab Cohort 5Total
Hispanic or Latino110002
Not Hispanic or Latino6786633
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Blinatumomab Cohort 1Blinatumomab Cohort 2Blinatumomab Cohort 3Blinatumomab Cohort 4Blinatumomab Cohort 5Total
American Indian or Alaska Native000000
Asian010001
Black (or African American)100001
Multiple000000
Native Hawaiian or Other Pacific Islander000000
White4786631
Other200002
08

Study locations

17 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Epworth Healthcare
    East Melbourne, Victoria 3002, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Hopital Henri Mondor
    Créteil Cedex, 94010, France
  • Hopital Saint Louis
    Paris Cedex 10, 75475, France
  • Universitaetsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Universitätsklinikum Frankfurt/Main
    Frankfurt am Main, 60590, Germany
  • Universitatsklinikum Ulm
    Ulm, 89081, Germany
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Azienda Ospedaliera Universitaria di Bologna Policlinico S Orsola Malpighi
    Bologna, 40138, Italy
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
    Brescia, 25123, Italy
  • IRCCS Ospedale San Raffaele
    Milano, 20132, Italy
  • IRCCS Istituto Clinico Humanitas
    Rozzano MI, 20089, Italy
  • Leicester Royal Infirmary
    Leicester, LE1 5WW, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2021, 47 months.

Results were first posted in Feb 2024, 2 years 5 months after primary completion.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 47 months is close to that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2016
First posted
Nov 11, 2016
StartActual
Sep 18, 2017
Primary completionActual
Sep 2, 2021
CompletionActual
Sep 2, 2021
Results first posted
Feb 2, 2024
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02961881
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 11, 2016
Start date
Sep 18, 2017
Primary completion
Sep 2, 2021
Completion
Sep 2, 2021
Results posted
Feb 2, 2024
Last update
Feb 2, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion